Skip to content
MarketScale
‹ Back to IndustriesSciences

What Impact Does the Coronavirus have on Global Business?

The potentially lasting effects of the Coronavirus, like those of the early-aughts SARS outbreak and the early-2010s’ avian-flu scare, are being felt not only in China, but across the globe. Originating in Wuhan, China, a city with a population of more than 10 million people, Coronavirus has kicked off a fast-spreading epidemic in the heart…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Ben Thomas · ClosingCoronavirusDiseaseFactories
Share
What Impact Does the Coronavirus have on Global Business?

Key takeaways

01

The potentially lasting effects of the Coronavirus, like those of the early-aughts SARS outbreak and the early-2010s’ avian-flu scare, are being felt not only in China, but across the globe.

02

Originating in Wuhan, China, a city with a population of more than 10 million people, Coronavirus has kicked off a fast-spreading epidemic in the heart…

The potentially lasting effects of the Coronavirus, like those of the early-aughts SARS outbreak and the early-2010s’ avian-flu scare, are being felt not only in China, but across the globe.

Originating in Wuhan, China, a city with a population of more than 10 million people, Coronavirus has kicked off a fast-spreading epidemic in the heart of Chinese manufacturing.

That location has resulted in ripple effects throughout the global economy as businesses that rely on Chinese manufacturing scramble for answers and investors and forecasters have a finger on the world economy’s proverbial panic button.

What outcomes and impacts are most likely in the wake of the disease?

Manufacturing Receives a Gut Punch

Though recent trends regarding the U.S. Institute for Supply Management seemed to suggest a renewed manufacturing boom – or at least a return to growth after a lengthy slowdown, the Coronavirus outbreak has thrown a China-sized wrench squarely in the middle of that progress.

Major players across a variety of industries are feeling the effects – from the actual act of shipping goods around the world to impacts on the oil and gas, construction and steel, and automotive industries, among others, manufacturing’s contraction is almost certain to put a hefty squeeze on the world’s production and transportation capabilities.

Tech, Even Among Giants, Hit Hard

In particular, the technology sector could be left reeling from the lengthening shuttering of Chinese production.

Apple has already closed all of the company’s offices and stores in China through Sunday, and factories for both the American tech giant and other major players could follow suit depending on the continued severity of the outbreak.

Analysts at Goldman Sachs predicted a 1.6-percentage-point drop in China’s first-quarter GDP growth, and a recommendation from the U.S. Centers for Disease Control and Prevention has spurred employers as large as Microsoft, Facebook and Amazon to implement various restrictions on travel in recent days.

Like companies across all the industries impacted by the outbreak, tech companies will be left scrambling for replacement manufacturing solutions if they mean to keep up with demand and avoid skidding off the road entirely.

The Global Economy Is in Flux

China’s central bank has already pledged to pump an enormous sum of money into the country’s economy in a last-ditch attempt to head off the worst of the disease’s financial impact, and markets around the globe are reacting negatively to the uncertainty surround the outbreak.

In the U.S., stocks are rebounding as a result of this attempted stimulus, as investors saw the DOW Jones Industrial Average balloon more than 400 points to fight back against recent dips related to the disease.

If previous American market reactions to similar outbreaks, which have been largely much ado about nothing, are to be trusted, the temporary panic could subside and give way to clearer heads, more central-bank stimulation and a steadier-than-expected market.

However, should the disease continue to spread and gain a more impactful stranglehold on the Chinese economy, there’s still a very real possibility for more disruption.

For the latest news, videos, and podcasts in B2B, be sure to subscribe to our industry publication.

Follow us on social media for the latest updates!

Twitter – @MarketScale

Facebook – facebook.com/marketscale

LinkedIn – linkedin.com/company/marketscale

About the author

Ben Thomas
Ben ThomasHead of Pro AV, MarketScale

Ben Thomas serves as Head of Pro AV at MarketScale, where he leads content and media strategy for the pro AV sector. With over 15 years of award-winning experience across large-scale events, network television, OTT platforms, and podcasting, he has guided major B2B brands including Intel, Sennheiser, Samsung, and Philips to billions of content interactions. He holds a B.A. in Mass Communications and is recognized for his expertise in podcast hosting, public speaking, marketing, and content strategy.

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one expert. Imagine publishing your whole team.

This article was produced through MarketScale. Create a free workspace and turn your own team's expertise into articles, video, and social posts. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Sciences Insights

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

The pharmaceutical industry is facing a significant challenge as over $300 billion in branded pharmaceutical revenue is set to lose patent protection by 2030. This revenue gap is driving the largest merger and acquisition cycle seen in a decade, with companies seeking external growth through acquisitions. This shift is impacting the entire life sciences supply chain, prompting strategic changes across the industry.

  • 01Over $300 billion in pharmaceutical revenue is at risk due to patent expirations by 2030.
  • 02Big Pharma is engaging in an aggressive cycle of mergers and acquisitions.
  • 03The acquisitions are reshaping the life sciences supply chain.

Jun 29, 2026

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences has initiated a Phase I clinical study at its UK facility for an oral solid dose formulation designed using artificial intelligence — what the company believes is the first AI-formulated drug to reach human clinical evaluation. The study, cleared by the UK's Medicines and Healthcare products Regulatory Agency, will assess safety and pharmacokinetics in healthy volunteers. The program, which used Intrepid Labs' machine learning algorithm, signals a broader shift in how contract drug development organizations are integrating AI across formulation and clinical workflows.

  • 01Quotient Sciences initiated a Phase I study of an AI-designed oral solid dose formulation at its UK facility following MHRA approval — the first such case the company believes has been reported.
  • 02The formulation was developed using Intrepid Labs' advanced machine learning algorithm in combination with Quotient Sciences' Translational Pharmaceutics platform.
  • 03The milestone is part of a broader CRDMO strategy to embed AI-enabled approaches across formulation development and clinical workflows, with implications for the wider contract pharma sector.

Jun 17, 2026

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences has initiated a Phase I clinical study of an oral solid dose formulation designed using AI, cleared by the UK's MHRA and conducted at the company's UK facility. The trial—built on machine learning algorithms from partner Intrepid Labs and Quotient's Translational Pharmaceutics platform—aims to validate AI as a direct contributor to formulation design rather than just an upstream analytical tool. Benchling characterizes the broader moment as biotech entering a "builder phase," in which leading organizations embed AI capability at the bench level rather than running isolated pilots.

  • 01Quotient Sciences has dosed healthy volunteers in a Phase I study it describes as the first clinical evaluation of an AI-designed oral formulation, following approval from the UK's MHRA.
  • 02The formulation was developed using advanced machine learning algorithms from Intrepid Labs, integrated with Quotient Sciences' Translational Pharmaceutics platform.
  • 03Benchling identifies a sector-wide shift toward embedding AI capability directly at the bench, moving beyond isolated pilots to structural adoption across biotech R&D.

Jun 17, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

Ben Thomas
Ben Thomas

Head of Pro AV

MarketScale

Ben Thomas serves as Head of Pro AV at MarketScale, where he leads content and media strategy for the pro AV sector. With over 15 years of award-winning experience across large-scale events, network television, OTT platforms, and podcasting, he has guided major B2B brands including Intel, Sennheiser, Samsung, and Philips to billions of content interactions. He holds a B.A. in Mass Communications and is recognized for his expertise in podcast hosting, public speaking, marketing, and content strategy.